Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 4.71 USD -4.27% Market Closed
Market Cap: 2.5B USD

Intrinsic Value

The intrinsic value of one RXRX stock under the Base Case scenario is 4.28 USD. Compared to the current market price of 4.71 USD, Recursion Pharmaceuticals Inc is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RXRX Intrinsic Value
4.28 USD
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Recursion Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about RXRX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is RXRX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Recursion Pharmaceuticals Inc.

Explain Valuation
Compare RXRX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about RXRX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Recursion Pharmaceuticals Inc

Current Assets 714.1m
Cash & Short-Term Investments 659.8m
Receivables 21.9m
Other Current Assets 32.4m
Non-Current Assets 685.4m
PP&E 181.2m
Intangibles 484.4m
Other Non-Current Assets 19.8m
Current Liabilities 155.1m
Accounts Payable 13.9m
Accrued Liabilities 83.7m
Other Current Liabilities 57.5m
Non-Current Liabilities 197.5m
Long-Term Debt 11.9m
Other Non-Current Liabilities 185.6m
Efficiency

Free Cash Flow Analysis
Recursion Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Recursion Pharmaceuticals Inc

Revenue
43.7m USD
Cost of Revenue
-69.5m USD
Gross Profit
-25.8m USD
Operating Expenses
-697.8m USD
Operating Income
-723.6m USD
Other Expenses
8m USD
Net Income
-715.5m USD
Fundamental Scores

RXRX Profitability Score
Profitability Due Diligence

Recursion Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

Recursion Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

RXRX Solvency Score
Solvency Due Diligence

Recursion Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Recursion Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RXRX Price Targets Summary
Recursion Pharmaceuticals Inc

Wall Street analysts forecast RXRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RXRX is 6.46 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

Lowest
Price Target
3.03 USD
36% Downside
Average
Price Target
6.46 USD
37% Upside
Highest
Price Target
10.5 USD
123% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Recursion Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RXRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

RXRX Insider Trading
Buy and sell transactions by insiders

RXRX News

Other Videos
What is the Intrinsic Value of one RXRX stock?

The intrinsic value of one RXRX stock under the Base Case scenario is 4.28 USD.

Is RXRX stock undervalued or overvalued?

Compared to the current market price of 4.71 USD, Recursion Pharmaceuticals Inc is Overvalued by 9%.

Back to Top